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Introduction
Heart transplantation (HTx) has provided a great sur-
vival benefit for patients with end-stage heart failure;
however, the majority of patients on the HTx waiting
list require long-term use of a left ventricular assist
device (LVAD) because of donor shortages1. Development
of intracerebral hemorrhage (ICH) is one of the most
serious complications in patients supported by LVADs,
who require extensive oral anticoagulant therapy2. ICH
associated with anticoagulation has a high mortality,
and more than 50% of patients die within 30 days3.
Thus, warfarin-related ICH is considered a medical
emergency especially in patients supported by LVADs.
Nevertheless, there are no guidelines for reversal of
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SUMMARY
Background: Intracerebral hemorrhage (ICH) is one of the most serious complications in patients supported by
a left ventricular assist device (LVAD). We evaluate the efficacy of prothrombin complex concentrate (PCC) for
rapid reversal of warfarin-induced anticoagulation in this population.
Methods: A total of 38 consecutive ICH events in patients supported by an LVAD between 1996 and 2007 were retro-
spectively reviewed. Fourteen ICH events were treated with fresh frozen plasma (FFP) (Group FFP) and 24 ICH events
were treated with PCC (Group PCC). The efficacy and outcome of PCC administration versus FFP were evaluated.
Results: The proportion of patients surviving after an ICH event was significantly smaller in Group FFP than
Group PCC (35.7% vs. 75.0%, p < 0.05). None of the patients in Group FFP were able to undergo heart transplan-
tation, whereas 21.4% patients in Group PCC successfully underwent heart transplantation.
Conclusion: Patients on LVAD are in need for intensified anticoagulation and are at high risk of ICH; therefore,
adequate use of PCC in the event of ICH could be of importance for survival and allow subsequent heart 
transplantation. [International Journal of Gerontology 2010; 4(3): 143–147]
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anticoagulation in such patients. Reversing warfarin-
induced anticoagulation by vitamin K is time consum-
ing4. The administration of fresh frozen plasma (FFP)
requires substantial intravenous volume5, which is not
appropriate in patients with heart failure. Prothrombin
complex concentrate (PCC), which contains a high con-
centration of the vitamin K-dependent coagulation
factors II, VII, IX and X, has been reported to be effective
for rapid reversal of warfarin-induced anticoagulation6,7.
PCC has been reported to reduce the prothrombin
time–international normalized ratio (PT-INR) faster
than FFP or vitamin K7,8. The PCC product (PPSB-HT;
Nihon Pharmaceuticals, Tokyo, Japan) became avail-
able at our institution in 2001, and it has been used
for emergency reversal of warfarin-induced anticoag-
ulant effects, such as ICH, intraabdominal hemorrhage
and cardiac tamponade.
In this study we investigated the effects of PCC for
rapid reversal of warfarin-induced anticoagulation in
patients supported by LVADs and who developed ICH.
Materials and Methods
Patients and study design
Thirty-eight consecutive ICH events, which occurred 
in patients supported by LVADs as a bridge to HTx
between April 1996 and March 2007 at our institution,
were retrospectively reviewed. All patients received
warfarin with targeted value of PT-INR between 3 and 4.
Rapid reversal of warfarin-induced anticoagulation
was attempted for all cases. Fourteen ICH events treated
by FFP were classified as Group FFP, and 24 ICH events
treated by PCC were classified as Group PCC. Vitamin K
was never used for patients in Group FFP nor Group
PCC. The coagulation status before and after ICH events
and the clinical outcomes were compared between
the groups. Patients who survived more than 1 month
after an ICH event were defined as “patients survived
through ICH events.” Patients who recovered from ICH
events with only limited neurological after effects were
able to return to the HTx waiting list; such patients
were defined as “patients survived and back on the
waiting list.”
FFP and PCC administrations are accepted and
financially covered by the National Health Insurance
System of Japan, and studied patients provided written
informed consent for drug administration. The present
study was approved by the Institutional Review Board
and Institutional Ethical Committee for Human Research
of the National Cardiovascular Center, and was executed
according to the Declaration of Helsinki.
Protocol for FFP and PCC administration
None of the ICH events were treated with vitamin K. 
In Group FFP, the FFP was initially administered after
the ICH event at the dosage of body weight (kg)×0.08×
(100-hematocrit/100) × 0.3 × 0.2 × 1000 (mL). If the PT-
INR was still greater than 2 after the initial FFP admin-
istration, additional FFP was administered. In Group
PCC, the initial dosage of 500–1000 units was adminis-
tered for 30–60 minutes, and if the INR was greater
than 2 after the initial PCC administration, additional
PCC was given.
Statistical analysis
Data are presented as mean ± standard deviation.
Normality was evaluated for each variable based on
normal distribution plots and histograms and by the
Kolmogorov-Smirnov test. Clinical characteristics, coag-
ulation status after anticoagulation reversal, and clinical
outcome were compared between groups by a Student
unpaired two-tailed t test or c2 analysis. Mortality after
IVH events was compared by Kaplan-Meier analysis and
the log rank test. All statistical analyses were performed
using JMP7.0 software (SAS Institute, Cary, NC, USA).
Results
The demographic and clinical data of the patients are
summarized in Table 1. The anticoagulant status before
and after the ICH event and the outcome in both groups
are shown in Table 2. The INR values before and on
the day of the ICH event were not different between
the groups; however, the INR values after treatment
were markedly reduced in Group PCC. The proportion
of patients who survived an ICH event was significantly
greater in Group PCC than Group FFP, although the
proportion of patients requiring subsequent neuro-
surgery was not significantly different between the
groups. The proportion of patients who returned to the
HTx waiting list tended to be greater in Group PCC
than Group FFP. None of the patients in Group FFP
underwent HTx compared with 21.4% of patients in
Group PCC (Table 2).
Representative computed tomography scans from
the two groups are shown in Figure.
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Discussion
Although this is a single center retrospective analysis,
the present study is the first head-to-head compari-
son of PCC versus FFP as a treatment for reversal of
warfarin-induced anticoagulation in a clinical setting in
the light of prognosis after treatment. The present study
demonstrated that (1) immediate PCC administration
after an ICH event in patients supported by LVADs was
effective in the prompt reversal of warfarin-induced
anticoagulation; and (2) the patients supported by LVADs
who had an ICH were able to have HTx only when they
were treated by PCC, not by FFP.
The majority of patients on the HTx waiting list
require long-term use of an LVAD because of donor
shortages1. In the REMATCH study2, sepsis was the
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Table 1. Demographic and clinical data from patients*
Parameter Group FFP (n = 14) Group PCC (n = 24) p
Age at LVAD implantation (yr) 33.1 ± 13.4 39.1 ± 5.9 0.064
Age at ICH events (yr) 33.6 ± 13.4 39.9 ± 6.3 0.056
Male 11 (78.6%) 3 (12.5%) 0.0002
Blood pressure
Systolic (mmHg) 102 ± 12.9 92 ± 15.9 0.053
Diastolic (mmHg) 61 ± 9.9 59 ± 10.9 0.576
Disease for LVAD implantation
Nonischemic cardiomyopathy 14 (100.0%) 24 (100.0%) –
Ischemic cardiomyopathy 0 (0.0%) 0 (0.0%) –
Type of LVAD
Toyobo 14 (100.0%) 23 (95.8%) 0.782
EVAHEART 0 (0.0%) 1 (4.2%) 0.782
Drugs
Warfarin 14 (100.0%) 24 (100.0%) –
Aspirin 12 (85.7%) 21 (87.5%) 0.734
β-blockers 12 (85.7%) 20 (83.3%) 0.833
ACE inhibitors or A-II antagonists 9 (64.2%) 16 (66.7%) 0.837
Intravenous inotropic agents 4 (28.5%) 4 (16.7%) 0.648
*Data presented as mean ± standard deviation or n (%). FFP = fresh frozen plasma; PCC = prothrombin complex concentrate; LVAD = left 
ventricular assist device; ICH = intracerebral hemorrhage; Toyobo = Toyobo-type extracorporeal LVAD (Toyobo Corp. Ltd., Tokyo, Japan); EVA-
HEART = implantable rotary blood pump LVAD (Sun Medical Technology Research Corp. Ltd., Nagano, Japan); ACE = angiotensin converting
enzyme; A-II = angiotensin II.
Table 2. Anticoagulant status pre- and post-intracerebral hemorrhage events (ICH) and outcome after ICH events
Parameter Group FFP (n = 14) Group PCC (n = 24) p
Anticoagulant status
Baseline INR at stable situation 3.4 ± 1.3 3.1 ± 1.0 0.224
INR on the day of ICH event 3.6 ± 2.0 3.0 ± 1.2 0.175
INR after administration of initial dose of FFP or PCC 2.1 ± 1.1 1.2 ± 0.3 0.004
Time required for INR reduction (min) 906.7 ± 437.8 135.4 ± 66.5 < 0.0001
Outcome after ICH event (%)
Patients requiring subsequent neurosurgery 42.9 33.3 0.570
Patients survived through ICH events 35.7 75.0 0.016
Patients survived and back on the waiting list 18.2 57.1 0.051
Patients survived to heart transplantation 0.0 21.4 < 0.0001
INR = international normalized ratio; FCC = fresh frozen plasma; PCC = prothrombin complex concentrate.
leading cause of death (29.5%) and stroke was the
third most frequent cause of death (9.0%) after LVAD
implantation. Development of ICH is one of the most
serious complications in patients supported by LVADs
who require extensive oral anticoagulant therapy2.
Therefore, rapid reversal of warfarin-induced antico-
agulation to prevent hematoma progression and to
facilitate hematoma evacuation4 has a decisive impact
on prognosis in such patients.
The anticoagulatory effect of warfarin is related to
its ability to inhibit synthesis of the vitamin K-dependent
clotting factors II, VII, IX and X. The appropriate way to
reverse the anticoagulation effect of warfarin depends
on the clinical situation. Minor or asymptomatic bleed-
ing needs less aggressive reversal, whereas serious
bleeding requires rapid reversal to avoid a subsequent
fatal event, regardless of the reason for anticoagulation.
For major bleeding, guidelines recommend the admin-
istration of vitamin K (5 mg intravenous or oral), and/or
PCC (50 U/kg), and/or FFP (15 mL/kg)9,10.
PCC contains a high level of the vitamin K-dependent
coagulation factors II, VII, IX and X7. PCC promotes a
much more rapid reduction of INR than FFP and/or
vitamin K5,8, which is explained by its higher concen-
tration of coagulation factors than FFP. A large volume
of FFP is required to achieve adequate INR reduction5,
because vitamin K-dependent coagulation factors vary
considerably in FFP, and is not appropriate for patients
with heart failure. Reversing anticoagulation with vita-
min K requires 4–24 hours5, which might result in a
fatal outcome after an ICH event; also its persistent
effect may promote clot formation4. Thus, vitamin K
administration is not a satisfactory treatment for LVAD-
supported patients with ICH.
PCC has been available at our institution since 2001;
therefore, patients in Group FFP consisted of patients
of an earlier era in our LVAD program than those in
Group PCC. The percentage of male patients was greater
in Group FFP because larger body mass index was
required for LVAD surgery at the earlier time.
Several studies have demonstrated the effect of
recombinant activated factor VII on warfarin reversal
and reported successful results in treating ICH events11,12.
Although recombinant activated factor VII does reduce
the INR, it does not lead to complete reversal of all
aspects of warfarin-associated coagulopathy13. Further
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Figure. Representative images of computed tomography head scan from patients in (A) Group FFP: A 50-year-old male 
developed intracerebral hemorrhage (ICH) in the right frontal lobe with a prothrombin time–international normalized ratio
(PT-INR) of 3.61. After administration of 4,160 mL of FFP resulting in a PT-INR of 1.73, the patient required neurosurgery.
Because of residual ICH, the patient required additional neurosurgery but eventually died. (B) In group PCC: a 41-year-old
female developed ICH in the right posterior lobe with a PT-INR of 3.47. The immediate administration of 1,000 units of PCC
resulted in a PT-INR of 1.21 within 20 minutes. The patient underwent heart transplantation 2.8 years after the ICH event
without neurological after effects. FCC = fresh frozen plasma; PCC = prothrombin complex concentrate.
studies are required to establish the differences among
PCCs, and the differences between PCCs and recombi-
nant activated factor VII on warfarin reversal to estab-
lish the optimal treatment strategy for emergency INR
reduction.
In conclusion, administration of PCC can result in 
a prompt reversal of warfarin-induced anticoagula-
tion and could be of importance for the survival of
patients supported by LVADs, who require intensified
anticoagulation therapy and who are at high risk 
of ICH.
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